Bevyxxa (betrixaban) for Venous Thomboemolism (VTE) - Community Event

  • 02 Nov 2017
  • 6:00 PM - 8:00 PM
  • TBD

Registration

  • Host: Kirk Vincent
    Sponsor: Portola Pharmaceuticals

    Recently, the FDA approved Bevyxxa (betrixaban) www.bevyxxa.com , the first and only anticoagulant for hospital and extended duration prophylaxis (35 to 42 days) of venous thromboembolism (VTE) in adult patients hospitalized for an acute medical illness who are at risk for thromboembolic complications due to moderate or severe restricted mobility and other risk factors for VTE.
    Portola anticipates the U.S. launch between September and November 2017. Further information on the risk of VTE can be found at www.VTEriskfacts.com.

    Venue: TBD


Host:  Kirk Vincent

Sponsor:  Portola Pharmaceuticals


Recently, the FDA approved Bevyxxa (betrixaban)  www.bevyxxa.com , the first and only anticoagulant for hospital and extended duration prophylaxis (35 to 42 days) of venous thromboembolism (VTE) in adult patients hospitalized for an acute medical illness who are at risk for thromboembolic complications due to moderate or severe restricted mobility and other risk factors for VTE.  

Portola anticipates the U.S. launch between September and November 2017.  Further information on the risk of VTE can be found at www.VTEriskfacts.com.  


Venue:  TBD



© Chattanooga Area Nurses in Advanced Practice

Website Designed By: Raymond C. Howard, MSN, APRN, CNP

Website Contributors: Dean Scott, MFA and Zoe Scott, MSN, APRN, CNP

Powered by Wild Apricot Membership Software